HIV Lymphoma and Burkitts Lymphoma

2020 ◽  
Vol 26 (3) ◽  
pp. 260-268
Author(s):  
Ariela Noy
Keyword(s):  
2001 ◽  
Vol 34 (8) ◽  
pp. 1344-1348
Author(s):  
Hidetaka Yamanaka ◽  
Akihiko Hori ◽  
Tomonori Sugiura ◽  
Tohru Kawai ◽  
Satoru Kawai ◽  
...  

Blood ◽  
2013 ◽  
Vol 122 (21) ◽  
pp. 4348-4348 ◽  
Author(s):  
Andrew McMillan ◽  
Kirit M Ardeshna ◽  
Jo Gambell ◽  
Andrew Jack ◽  
Amy Kirkwood ◽  
...  

Abstract Introduction R-CHOP is the standard of care for patients with diffuse large B cell lymphoma (DLBCL) however poor risk patients (IPI 3-5) still have an inadequate outcome. Neither first remission high dose chemotherapy and peripheral blood stem cell transplantation (HDC+PBSCT) nor selection of cases for intensification by interim PET scanning have demonstrated a proven benefit. In the case of Burkitts lymphoma (BL) there is a paucity of data on the addition of Rituximab to the CODOX-M and IVAC regimen. Patients and Methods 113 patients with DLBCL and 37 with BL were recruited from 53 UK sites between May 2008 and April 2013. Median age was 49 years (18-65). For DLBCL patients IPI scores were 3 – 72 ( 64%), 4 -40 (35%) and 5 – 1 (1%). All patients received the modified CODOX-M and IVAC regimen including all CNS directed therapy( Mead et al Ann Oncol. 2002 Aug;13(8):1264-74) and 8 doses of rituximab. The primary end point of the study was Progression Free survival (PFS) and secondary endpoints included toxicity and CR rate. Results The main toxicities reported were neutropenia ( 89% grade 3 or 4), thrombocytopenia (84.2% grade 3 or 4), infection 61.6% grade 3 or 4 and mucositis (30.1% grade 3 or 4). 4 patients were excluded from toxicity assessment as they did not start therapy after registration. There were 8 treatment related deaths observed (infection with neutropenia (5), GI haemorrhage (1), acute cerebral haemorrhage (1) and bowel perforation (1) ). 78 patients with DLBCL and 31 with BL have completed all therapy ( 78.5 % of patients with available data) with an overall response rate of 92 % for DLBCl and 94% for BL. In patients who completed all therapy CR was achieved in 34 (44%), CR (u) in 8 (10%) and PR in 30 (38%) for DLBCL patients and CR was achieved in 21 (68%), CR (u) in 6 (19%) and PR in 2 (6%) in BL patients. 3 patients ( 2 DLBCL and 1 BL) who progressed during therapy have been included in the response analysis. End of treatment PET scanning was not obligatory. 80 patients with DLBCL and 30 patients with BL remain alive and without progression at a median follow up of 18.6 and 19.3 months respectively. Conclusion The R-CODOX-M -R-IVAC regimen can be delivered to patients with poor risk DLBCL in a multicentre setting. High rates of haematological toxicity and consequent infection are inevitable with treatment of this intensity but appear acceptable when compared with other treatments such as HDC+PBSCT. Response rates are encouraging in view of the very poor risk IPI profile of the patients included in this study. Burkitts lymphoma patients also achieved an excellent response rate with no apparent additional toxicity attributable to the addition of rituximab to the regimen. We currently plan the first analysis for the primary endpoint of PFS in 2015. The Trial was supported by Leukaemia and Lymphoma Research (LLR). Disclosures: McMillan: Roche: Consultancy, Honoraria; Amgen: Research Funding. Off Label Use: Rituximab usage in Burkitts Lymphoma. Ardeshna:Roche: Honoraria, Research Funding. Jack:Roche/Genentech: Research Funding. Patmore:Roche: Consultancy, Honoraria. Pettengell:Roche: Honoraria; Amgen: Honoraria. Linch:Roche: Honoraria, Research Funding.


Blood ◽  
2006 ◽  
Vol 108 (11) ◽  
pp. 1191-1191
Author(s):  
Rong Hu ◽  
Galina L. Mukhina ◽  
Michael I. Collector ◽  
Soo Hee Lee ◽  
Richard J. Jones ◽  
...  

Abstract Glycosylphosphatidylinositol is an important means of anchoring many cell surface proteins. Glycosylphosphatidylinositol anchored proteins (GPI-AP) are distributed on all hematopoietic lineages, but are absent on hematopoietic cells from patients with paroxysmal nocturnal hemoglobinuria (PNH). The absence of GPI-AP in PNH is due to mutations in PIG-A, whose product is necessary for the 1st step in GPI biosynthesis. A small percentage of GPI-AP deficient cells can be found in cell lines and that these GPI-APlo/neg cells do not harbor PIG-A mutations. The significance and mechanism of the GPI-AP deficiency in these cells are unclear. We found that 25% of the Burkitts’ lymphoma cell line, Ramos, is GPI-APlo/neg after staining with FLAER and that these GPI-APlo/neg cells do not harbor PIG-A mutations. After 2 days cultured in regular medium, the GPI-APlo/neg Ramos cells reverted to a mix of GPI-APlo/neg and GPI-APpos cells demonstrating that the GPI-APlo/neg cells appear to be precursors to the GPI-APpos cells. An in vitro assay for early steps in GPI anchor biosynthesis using UDP-[3H]GlcNAc found that the GPI-APlo/neg cells generated reduced amounts of the 1st and 2nd GPI intermediates, GlcNAc-PI and GlcN-PI. RT-PCR of the 24 known genes involved in GPI anchor biosynthesis revealed silencing of PIGL and to a lesser extent, PIGY. Methylation specific PCR demonstrated that PIGL was hypermethylated in the FLAERlo/neg Ramos cells. Furthermore, culturing the FLAERlo/neg Ramos cells in 5-Aza-2′ deoxycytidine greatly increased the percentage of cells displaying surface GPI-AP, suggesting that demethylating PIGL and perhaps PIGY may restore surface expression of GPI-AP. We hypothesized that primitive HSC may also enriched for GPI-APlo/neg cells. Thus, we isolated small lineage depleted Fr25Lin− cells from C57Bl6/NCR (Ly 5.2) mice as described1 and found that 30% were GPI-APlo/neg. Fr25lin−GPI-APlo/neg cells were highly enriched for HSC/progenitor cells using hematopoietic colony forming assays. We next transplanted lethally irradiated female recipients with either 100 Fr25Lin−FLAERlo/neg or Fr25Lin−FLAERpos, respectively. 3/4 animals transplanted with Fr25lin−FLAERlo/neg cells survived 17 weeks and revealed 81%, 85% and 90% engraftment; 2/4 animals transplanted with 100 Fr25lin−FLAER pos cells survived 17 weeks with 17% and 48% engraftment. Similar to the Ramos cells, RT-PCR analysis of the Fr25lin−GPI-APlo/neg cells revealed silencing of pigl and to a lesser extent, pigy. In this study, we found that reduced surface expression of GPI-AP is a common feature of cancer cell lines and primitive hematopoietic progenitor cells. In contrast to the fixed GPI-AP deficiency in HSC from PNH patients, the absence of GPI-AP in certain cancer cell lines and normal HSC is not fixed; the progeny of these cells acquire GPI-AP upon cellular differentiation. Furthermore, our data suggest that silencing of the genes required for early steps in GPI anchor biosynthesis, most notably PIG-L and PIG-Y, are responsible for the paucity of GPI-AP on the HSC/progenitor cells.


Author(s):  
L. Ardekian ◽  
D. Rosen ◽  
I. Abu-el-Naaj ◽  
M. Peled ◽  
D. Laufer

Sign in / Sign up

Export Citation Format

Share Document